Clostridium butyricum Bacteremia Associated with Probiotic Use, Japan

Sada, Ryuichi Minoda; Matsuo, Hiroo; Motooka, Daisuke; Kutsuna, Satoshi; Hamaguchi, Shigeto; Yamamoto, Go; Ueda, Akiko

doi:10.3201/eid3004.231633

Advanced Search

Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

Advanced Search
Custom Query

All these words:

For very narrow results

This exact word or phrase:

When looking for a specific result

Any of these words:

Best used for discovery & interchangable words

None of these words:

Recommended to be used in conjunction with other fields

Language:

Dates

Publication Date Range:

to

Document Data

Title:

Document Type:

Library

Collection:

Series:

People

Author:

Clear All

Query Builder

Query box

Clear All

For additional assistance using the Custom Query please check out our Help Page

i

Clostridium butyricum Bacteremia Associated with Probiotic Use, Japan

4 2024
By Sada, Ryuichi Minoda ; Matsuo, Hiroo ; Motooka, Daisuke ; ...
http://dx.doi.org/10.3201/eid3004.231633
Source: Emerg Infect Dis. 2024; 30(4):665-671

[PDF-517.54 KB]

English

Details Supporting Files You May Also Like

Details:

Alternative Title:

Emerg Infect Dis
Personal Author:

Sada, Ryuichi Minoda ; Matsuo, Hiroo ; Motooka, Daisuke ; Kutsuna, Satoshi ; Hamaguchi, Shigeto ; ... More +

Sada, Ryuichi Minoda ; Matsuo, Hiroo ; Motooka, Daisuke ; Kutsuna, Satoshi ; Hamaguchi, Shigeto ; Yamamoto, Go ; Ueda, Akiko Less -
Description:

Clostridium butyricum, a probiotic commonly prescribed in Asia, most notably as MIYA-BM (Miyarisan Pharmaceutical Co., Ltd.; https://www.miyarisan.com), occasionally leads to bacteremia. The prevalence and characteristics of C. butyricum bacteremia and its bacteriologic and genetic underpinnings remain unknown. We retrospectively investigated patients admitted to Osaka University Hospital during September 2011-February 2023. Whole-genome sequencing revealed 5 (0.08%) cases of C. butyricum bacteremia among 6,576 case-patients who had blood cultures positive for any bacteria. Four patients consumed MIYA-BM, and 1 patient consumed a different C. butyricum-containing probiotic. Most patients had compromised immune systems, and common symptoms included fever and abdominal distress. One patient died of nonocclusive mesenteric ischemia. Sequencing results confirmed that all identified C. butyricum bacteremia strains were probiotic derivatives. Our findings underscore the risk for bacteremia resulting from probiotic use, especially in hospitalized patients, necessitating judicious prescription practices.
Subjects:

[+]

Bacteremia Clostridium Butyricum Humans Probiotics Retrospective Studies
Keywords:

[+]

Bacteremia Bacteria Burkholderia Pseudomallei History Inappropriate Prescribing Japan Melioidosis Probiotics
Source:

Emerg Infect Dis. 2024; 30(4):665-671
Pubmed ID:

38413242
Pubmed Central ID:

PMC10977840
Document Type:

Journal Article
Place as Subject:

Japan
Volume:

30
Issue:

4
Collection(s):

Emerging Infectious Diseases
Main Document Checksum:

[+]

urn:sha256:b37ff8dddf07980a6b886c211418e3b3752793dae9fbbb5bfd42ff0b2a599ca9
Download URL:

https://stacks.cdc.gov/view/cdc/152973/cdc_152973_DS1.pdf
File Type:

	23-1633-F.gif	gif
	23-1633-F.jpg	jpeg
	23-1633-Techapp-s1.pdf	pdf
	23-1633.nxml	xml

More +